case studies of EUFECT® LNP formulations: LNP Technology Platform - Steinbeis-Innovationszentrum Zellkulturtechnik

Evidence

Case Studies & Validation

The following case studies demonstrate the transfection performance of EUFECT^® LNP formulations across three biologically distinct and clinically relevant cell models: adherent tumour cell lines, human primary fibroblasts, and induced pluripotent stem cells (iPSC). In each experiment, EUFECT^®-based LNPs were tested head-to-head against equivalent formulations prepared with commercially available ionizable lipids under identical conditions. All LNPs were loaded with eGFP-encoding mRNA to enable direct, quantitative visualisation of transfection efficiency, assessed 24 hours post-transfection by three complementary read-outs.

Brightfield

Phase-contrast microscopy reveals cell morphology, monolayer density, and integrity — confirming viability independent of transfection status.

Fluorescence (eGFP)

eGFP emission (ex. 488 nm / em. 507 nm) directly visualises LNP uptake and mRNA translation.

Flow Cytometry (FITC)

Single-cell FITC histograms quantify % eGFP⁺ cells. The vertical gate line separates autofluorescence (left) from eGFP-specific signal (right).

★ EUFECT^® columns are highlighted in teal throughout. All fluorescence intensities to the right of the vertical gate line in the Flow Cytometry row represent signals that exceed cellular autofluorescence.

Adherent Tumour Cell Line (HSC)

eGFP mRNA-LNP · 24 h incubation

	Market-Standard 1	Market-Standard 2	Market-Standard 3	EUFECT^® Blue ★ EUFECT^®
Brightfield Phase-contrast micrograph showing cell morphology and density
Fluorescence eGFP emission (ex. 488 nm / em. 507 nm)
Flow Cytometry FITC histogram; vertical gate line separates autofluorescence (left) from eGFP signal (right)
	All fluorescence intensities to the right of the gate line exceed cellular autofluorescence.

Human Primary Fibroblasts

GFP mRNA-LNP · 24 h incubation

	Market-Standard 3	Market-Standard 4	Market-Standard 5	Market-Standard 6	EUFECT® Red ★ EUFECT^®
Brightfield Phase-contrast micrograph showing cell morphology and density
Fluorescence eGFP emission (ex. 488 nm / em. 507 nm)
Flow Cytometry FITC histogram; vertical gate line separates autofluorescence (left) from eGFP signal (right)
	All fluorescence intensities to the right of the gate line exceed cellular autofluorescence.

Human iPSC (Induced Pluripotent Stem Cells)

eGFP mRNA-LNP · 24 h incubation

	Market-Standard 4	EUFECT^® Gold ★ EUFECT^®
Brightfield Phase-contrast micrograph showing cell morphology and density
Fluorescence eGFP emission (ex. 488 nm / em. 507 nm)
Flow Cytometry FITC histogram; vertical gate line separates autofluorescence (left) from eGFP signal (right)
	All fluorescence intensities to the right of the gate line exceed cellular autofluorescence.

Case Studies